ImmunoGenesis Announces STING Agonist Presentation at Cancer Conference

Biotech firm to showcase IND-enabling data for IMGS-203 therapy targeting glioblastoma at AACR 2026 meeting.

Apr. 15, 2026 at 1:12pm

Got story updates? Submit your updates here. ›

An abstract, ghostly X-ray image revealing the complex internal structure of a brain tumor, conveying the scientific and medical nature of this new cancer treatment.A cutting-edge cancer therapy aims to harness the immune system to fight an aggressive brain tumor.Houston Today

ImmunoGenesis, a clinical-stage biotech company, announced it will present details on the IND-enabling work for its IMGS-203 therapy, a potent Stimulator of Interferon Genes (STING) agonist, at the upcoming American Association for Cancer Research (AACR) 2026 Annual Meeting. The IMGS-203 therapy is being developed to treat glioblastoma multiforme (GBM), an aggressive form of brain cancer.

Why it matters

STING agonists have shown promise in stimulating the immune system to attack cancer cells, but delivering these therapies effectively to the tumor microenvironment in GBM has been a challenge. ImmunoGenesis' approach aims to overcome the immunosuppressive nature of GBM tumors by combining potent STING activation with a localized delivery method.

The details

The IMGS-203 therapy is designed to activate the STING pathway, which plays a key role in the body's immune response against cancer. By delivering the STING agonist directly to the tumor site, ImmunoGenesis hopes to overcome the immunosuppressive nature of the GBM microenvironment and trigger a robust anti-tumor immune response.

  • The AACR 2026 Annual Meeting is scheduled for April 12-16, 2026.
  • ImmunoGenesis will present details on the IND-enabling work for IMGS-203 at the conference.

The players

ImmunoGenesis

A clinical-stage biotech company developing novel cancer immunotherapies, including the IMGS-203 STING agonist for glioblastoma.

STING

The Stimulator of Interferon Genes (STING) pathway is a key component of the body's innate immune response against cancer and other diseases.

Glioblastoma Multiforme (GBM)

An aggressive and difficult-to-treat form of brain cancer with a poor prognosis.

Got photos? Submit your photos here. ›

What’s next

ImmunoGenesis plans to submit an Investigational New Drug (IND) application for IMGS-203 to the FDA in the coming months, following the presentation of the IND-enabling data at the AACR 2026 meeting.

The takeaway

The presentation of IMGS-203 data at AACR 2026 represents an important milestone for ImmunoGenesis as it advances this novel STING agonist therapy toward clinical trials for the treatment of the highly aggressive and difficult-to-treat glioblastoma brain cancer.